Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity[1].
in vivo
Lilotomab (0.5 mg/kg; i.v.; once) inhibits tumor growth in mice[1].
Animal Model:
SCID mice (DOHH2 cell xenografts)[1]
Dosage:
0.5mg/kg
Administration:
I.v.; once
Result:
Inhibited tumor growth and increased mouse survival.
References
[1] Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. J Nucl Med. 2020 Oct;61(10):1468-1475. DOI:10.2967/jnumed.119.237230
